产品详情
Rapamycin (Sirolimus) 雷帕霉素(西罗莫司)
产品标签
Rapamycin雷帕霉素;Sirolimus西罗莫司;3-MA 3-甲基腺嘌呤;自吞噬抑制剂 Autophagy inhibitor;mTOR;CAS:53123-88-9;
产品信息
产品名称 | 产品编号 | CAS NO. | 规格 | 价格(元) |
Rapamycin (Sirolimus) 雷帕霉素(西罗莫司) | MZ0201-10MG | 53123-88-9 | 10mg | 248 |
Rapamycin (Sirolimus) 雷帕霉素(西罗莫司) | MZ0201-50MG | 53123-88-9 | 50mg | 480 |
Rapamycin (Sirolimus) 雷帕霉素(西罗莫司) | MZ0201-100MG | 53123-88-9 | 100mg | 680 |
Rapamycin (Sirolimus) 雷帕霉素(西罗莫司) | MZ0201-500MG | 53123-88-9 | 500mg | 2680 |
Rapamycin (Sirolimus) 雷帕霉素(西罗莫司) | MZ0201-1000MG | 53123-88-9 | 1g | 3980 |
产品描述
雷帕霉素(Rapamycin),也称西罗莫司(Sirolimus),AY 22989,一种分离自细菌的大环内酯化合物,抗真菌剂和免疫抑制剂。雷帕霉素是一种特异性的mTOR抑制剂,IC50为~0.1nM(HEK293细胞)。与细胞内受体FKBP-12结合形成复合物,之后作用于mTOR中的FRB结构域从而抑制蛋白活性。雷帕霉素处理细胞引起p70 S6激酶的去磷酸化和功能失活(IC50 = 50 pM)。还能引起4E-BP1/PHAS1去磷酸化,进而促使其结合并失活eIF4E。雷帕霉素能够阻断蛋白合成和诱导细胞周期停滞在G1期。还能诱导酵母和哺乳动物细胞的自吞噬现象。能驱使人多能干细胞(hPSC)分化成中内胚层和血液祖细胞。
产品特性
使用方法【源自文献,仅作参考】
文献1,Iwamaru A et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 2007 Mar 22; 26(13):1840-51. PMID: 17001313 体外研究: 细胞类型(Cell type):Human malignant glioma U87-MG and A172 cells 药物配制(Preparation):Rapamycin was dissolved in DMSO to make 1mM stock solution and stored at -20℃. 实验方法(Assay):Tumor cells were exposed to rapamycin (1, 10 or 100 nm) for 24 or 48 h. The cytotoxic effect of rapamycin was determined using a WST-1 cell proliferation assay. |
文献2,Caramés B et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis. 2012 Apr;71(4):575-81. PMID: 22084394 体内研究: 动物模型(Animal Model):Experimental osteoarthritis was induced in 2-month-old male C57Bl/6J mice 药物配制(Preparation):Rapamycin was dissolved in DMSO at 25mg/ml and stored at -20℃. For injection, the stock solution was diluted in phosphate buffered saline (PBS). 注射剂量(Dosages):Mice received daily intraperitoneal injections of rapamycin at 1 mg/kg body weight/dose in a total injection volume of 0.3 ml for 10 weeks and control animals received the DMSO vehicle at 0.4% in a total injection volume of 0.3 ml. 给药途径(Administration):Intraperitoneal (i.p.) injection |
文献3,Eshleman JS et al. Inhibition of the Mammalian Target of Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy. Cancer Res. 2002 Dec 15;62(24):7291-7. PMID: 12499272 体外研究: 细胞类型(Cell type):A172, U87, and U118 malignant glioma cell lines 药物配制(Preparation):Rapamycin (NSC 226080) was dissolved in ethanol to yield a 5 mg/ml stock solution, which was stored at −20°C. 实验方法(Assay):Tumor cells were incubated with 0 or 100 nM rapamycin at 37°C for 72 h and then processed in a MTS assay. 体内研究: 动物模型(Animal Model):8-10-week-old female athymic nude mice by s.c. injection of 2-5 million U87 cells 药物配制(Preparation):For rapamycin injections, stock rapamycin was diluted first in sterile 10% PEG400/8% ethanol and then in an equal volume of sterile 10% Tween 80 for a final concentration of 20 μg rapamycin/100 μl. Rapamycin was delivered by i.p. injection, and the doses of rapamycin were calculated assuming that all mice weighed 20 g. 给药途径(Administration):Intraperitoneal (i.p.) injection |
注意事项
相关产品
货号 | 名称 | 规格 | 价格(元) |
MZ0002-10MG | 3-Methyladenine (3-MA) 3-甲基腺嘌呤 | 10mg | 185 |
MZ0341-5MG | Dorsomorphin (Compound C, BML-275) | 5mg | 850 |
MZ0342-5MG | Dorsomorphin Dihydrochloride | 5mg | 750 |
MZ1701-0001MG | MG-132 蛋白酶体抑制剂 | 1mg | 215 |
— —Written/Edited by V. Shallan【版权归MKBio懋康所有】
上海懋康生物科技有限公司是一家涉足于生命科学和生物技术领域研究的试剂、仪器和实验室消耗品与实验服务工作,主要从事细胞生物学、植物学、分子生物学、免疫学、生物化学、蛋白组学。生物制药与诊断试剂研发生产等领域。 本公司秉承“以人为本,以诚为信、合同守信”的经营理念。坚持"品质保障"的原则为广大客户提供优质产品。
Rapamycin 雷帕霉素(西罗莫司)/53123-88-9 mTOR pathway
Rapamycin 雷帕霉素(西罗莫司)/53123-88-9 mTOR pathway
Rapamycin 雷帕霉素(西罗莫司)/53123-88-9 mTOR pathway
*您想获取产品的资料:
个人信息: